The clinical applications of genome editing in HIV.

PubWeight™: 0.79‹?›

🔗 View Article (PMID 27053530)

Published in Blood on April 06, 2016

Authors

Cathy X Wang1, Paula M Cannon1

Author Affiliations

1: Department of Molecular Microbiology and Immunology, University of Southern California Keck School of Medicine, Los Angeles, CA.

Associated clinical trials:

Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 for HIV (Zinc-Finger) | NCT00842634

Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients | NCT01044654

Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects | NCT01252641

Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-T | NCT01543152

Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART | NCT02225665

Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients | NCT02500849

A Phase I Study of T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728mR in HIV-Infected Patients | NCT02388594

Articles cited by this

Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature (2005) 19.15

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science (1997) 18.10

Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell (1996) 17.81

Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature (1996) 15.91

Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature (1997) 15.49

A whole-genome association study of major determinants for host control of HIV-1. Science (2007) 15.19

Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol (2008) 14.75

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med (1999) 12.68

Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med (2009) 11.68

ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol (2013) 11.58

Change in coreceptor use correlates with disease progression in HIV-1--infected individuals. J Exp Med (1997) 11.01

The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med (1996) 10.62

Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med (2003) 9.75

Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery. Nat Biotechnol (2007) 9.23

Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science (1999) 8.43

Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med (2014) 7.64

Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol (2010) 6.55

Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci U S A (2002) 6.09

GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol (2014) 5.69

A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction. Curr Biol (2005) 5.24

Homing endonucleases: keeping the house in order. Nucleic Acids Res (1997) 5.03

Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. Blood (2010) 4.99

Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci U S A (2006) 4.23

Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis (2009) 3.91

RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med (2010) 3.53

Hematopoietic and endothelial differentiation of human induced pluripotent stem cells. Stem Cells (2009) 3.46

Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases. Nat Biotechnol (2014) 2.99

A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc Natl Acad Sci U S A (2004) 2.99

Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion. PLoS Pathog (2009) 2.92

HIV-1 proviral DNA excision using an evolved recombinase. Science (2007) 2.81

HIV Restriction Factors and Mechanisms of Evasion. Cold Spring Harb Perspect Med (2012) 2.72

Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. Cell Stem Cell (2014) 2.55

Targeted genome editing in human repopulating haematopoietic stem cells. Nature (2014) 2.49

Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Sci Rep (2013) 2.48

Genotoxicity of retroviral integration in hematopoietic cells. Mol Ther (2006) 2.34

RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc Natl Acad Sci U S A (2014) 2.32

Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat Med (2009) 2.21

Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis (2013) 2.17

Conservative homologous recombination preferentially repairs DNA double-strand breaks in the S phase of the cell cycle in human cells. Nucleic Acids Res (2004) 2.02

Quantitative live cell imaging reveals a gradual shift between DNA repair mechanisms and a maximal use of HR in mid S phase. Mol Cell (2012) 1.91

Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol Ther (2005) 1.89

Simultaneous zinc-finger nuclease editing of the HIV coreceptors ccr5 and cxcr4 protects CD4+ T cells from HIV-1 infection. Blood (2013) 1.80

Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat Biotechnol (2015) 1.71

Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases. PLoS Pathog (2011) 1.50

Quantifying genome-editing outcomes at endogenous loci with SMRT sequencing. Cell Rep (2014) 1.50

Genomic editing of the HIV-1 coreceptor CCR5 in adult hematopoietic stem and progenitor cells using zinc finger nucleases. Mol Ther (2013) 1.49

Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Δ32 mutation confers resistance to HIV infection. Proc Natl Acad Sci U S A (2014) 1.49

Zinc-finger-nucleases mediate specific and efficient excision of HIV-1 proviral DNA from infected and latently infected human T cells. Nucleic Acids Res (2013) 1.48

Characterization of anti-CCR5 ribozyme-transduced CD34+ hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo. Mol Ther (2000) 1.47

Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus. Mol Ther (2007) 1.44

Genome editing technologies: defining a path to clinic. Mol Ther (2015) 1.41

CCR2 chemokine receptor and AIDS progression. Nat Med (1997) 1.34

Efficient modification of CCR5 in primary human hematopoietic cells using a megaTAL nuclease and AAV donor template. Sci Transl Med (2015) 1.30

Selective survival of peripheral blood lymphocytes in children with HIV-1 following delivery of an anti-HIV gene to bone marrow CD34(+) cells. Mol Ther (2005) 1.28

In vivo selection of MGMT(P140K) lentivirus-transduced human NOD/SCID repopulating cells without pretransplant irradiation conditioning. J Clin Invest (2003) 1.26

Chemokine receptor 5 knockout strategies. Curr Opin HIV AIDS (2011) 1.22

Successful targeting and disruption of an integrated reporter lentivirus using the engineered homing endonuclease Y2 I-AniI. PLoS One (2011) 1.21

Preferential survival of CD4+ T lymphocytes engineered with anti-human immunodeficiency virus (HIV) genes in HIV-infected individuals. Hum Gene Ther (2005) 1.17

Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors. Nat Biotechnol (2015) 1.17

TALENs facilitate targeted genome editing in human cells with high specificity and low cytotoxicity. Nucleic Acids Res (2014) 1.16

Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5. Hum Gene Ther (2013) 1.14

Zinc-finger nuclease editing of human cxcr4 promotes HIV-1 CD4(+) T cell resistance and enrichment. Mol Ther (2012) 1.10

Generation of an HIV resistant T-cell line by targeted "stacking" of restriction factors. Mol Ther (2013) 1.10

Genotoxicity of retroviral hematopoietic stem cell gene therapy. Expert Opin Biol Ther (2011) 1.08

The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA. Retrovirology (2015) 1.06

HIV therapeutic vaccines: moving towards a functional cure. Curr Opin Immunol (2015) 1.06

HIV-1 resistance conferred by siRNA cosuppression of CXCR4 and CCR5 coreceptors by a bispecific lentiviral vector. AIDS Res Ther (2005) 1.05

Generation of CD34+ cells from CCR5-disrupted human embryonic and induced pluripotent stem cells. Hum Gene Ther (2011) 1.05

Phenotypic knockout of HIV type 1 chemokine coreceptor CCR-5 by intrakines as potential therapeutic approach for HIV-1 infection. Proc Natl Acad Sci U S A (1997) 1.03

A high excision potential of TALENs for integrated DNA of HIV-based lentiviral vector. PLoS One (2015) 1.01

In vivo selection for human and murine hematopoietic cells transduced with a therapeutic MGMT lentiviral vector that inhibits HIV replication. Mol Ther (2004) 0.99

T-cell therapies for HIV. Immunotherapy (2013) 0.99

Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9. J Gen Virol (2015) 0.97

Pre-clinical modeling of CCR5 knockout in human hematopoietic stem cells by zinc finger nucleases using humanized mice. J Infect Dis (2013) 0.97

Creating genetic resistance to HIV. Curr Opin Immunol (2012) 0.93

Network-based prediction and analysis of HIV dependency factors. PLoS Comput Biol (2011) 0.91

The epidemiology of HIV coreceptor tropism. Eur J Med Res (2007) 0.86

Protecting from R5-tropic HIV: individual and combined effectiveness of a hammerhead ribozyme and a single-chain Fv antibody that targets CCR5. Gene Ther (2004) 0.85

Identification of novel HIV-1 dependency factors in primary CCR4(+)CCR6(+)Th17 cells via a genome-wide transcriptional approach. Retrovirology (2015) 0.85

Genetic associations of variants in genes encoding HIV-dependency factors required for HIV-1 infection. J Infect Dis (2010) 0.84

Off-target-free gene delivery by affinity-purified receptor-targeted viral vectors. Nat Commun (2015) 0.83

Exclusive Transduction of Human CD4+ T Cells upon Systemic Delivery of CD4-Targeted Lentiviral Vectors. J Immunol (2015) 0.80

Universal Tre (uTre) recombinase specifically targets the majority of HIV-1 isolates. J Int AIDS Soc (2014) 0.79

HIV eradication--from Berlin to Boston. Nat Biotechnol (2014) 0.79